Literature DB >> 24139923

Roux-en-Y gastric bypass compared with aggressive diet and exercise therapy for morbidly obese patients awaiting renal transplant: a decision analysis.

Rashikh A Choudhury1, Kenric M Murayama2, Peter L Abt2, Henry A Glick2, Ali Naji2, Noel N Williams2, Kristoffel R Dumon2.   

Abstract

BACKGROUND: The optimal management of morbidly obese patients awaiting renal transplant is controversial and unknown. The objective of this study was to compare the impact of Roux-en-Y gastric bypass (RYGB) versus diet and exercise on the survival of morbidly obese patients with end-stage renal disease awaiting renal transplant.
METHODS: A decision analytic Markov state transition model was designed to simulate the life of morbidly obese patients with end-stage renal disease awaiting transplant. Life expectancy after RYGB and after 1 and 2 years of diet and exercise was estimated and compared in the framework of 2 clinical scenarios in which patients above a body mass index (BMI) of 35 kg/m(2) or above a BMI of 40 kg/m(2) were ineligible for transplantation, reflecting the BMI restrictions of many transplant centers. In addition to base case analysis (45 kg/m(2) BMI preintervention), sensitivity analysis of initial BMI was completed. Markov model parameters were extracted from the literature.
RESULTS: RYGB improved survival compared with diet and exercise. Patients who underwent RYGB received transplants sooner and in higher frequency. Using 40 kg/m(2) as the upper limit for transplant eligibility, base case patients who underwent RYGB gained 5.4 years of life, whereas patients who underwent 1 and 2 years of diet and exercise gained 1.5 and 2.8 years of life, respectively. Using 35 kg/m(2) as the upper limit, RYGB base case patients gained 5.3 years of life, whereas patients who underwent 1 and 2 years of diet and exercise gained .7 and 1.5 years of life, respectively.
CONCLUSIONS: In morbidly obese patients with end-stage renal disease, RYGB may be more effective than optimistic weight loss outcomes after diet and exercise, thereby improving access to renal transplantation.
Copyright © 2014 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Diet; Exercise; Markov; Renal transplant; Roux-en-Y gastric bypass; Transplant; gastric bypass

Mesh:

Year:  2013        PMID: 24139923     DOI: 10.1016/j.soard.2013.04.016

Source DB:  PubMed          Journal:  Surg Obes Relat Dis        ISSN: 1550-7289            Impact factor:   4.734


  6 in total

1.  Bariatric Surgery in Patients with Dialysis-Dependent Renal Failure.

Authors:  Anthony B Mozer; John R Pender; William H H Chapman; Megan E Sippey; Walter J Pories; Konstantinos Spaniolas
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

Review 2.  A Scoping Review of Artificial Intelligence and Machine Learning in Bariatric and Metabolic Surgery: Current Status and Future Perspectives.

Authors:  Athanasios G Pantelis; Georgios K Stravodimos; Dimitris P Lapatsanis
Journal:  Obes Surg       Date:  2021-07-15       Impact factor: 4.129

3.  Sleeve Gastrectomy Compared with Gastric Bypass for Morbidly Obese Patients with End Stage Renal Disease: a Decision Analysis.

Authors:  Rashikh A Choudhury; Gerard Hoeltzel; Kas Prins; Eric Chow; Hunter B Moore; Peter J Lawson; Dor Yoeli; Akshay Pratap; Peter L Abt; Kristoffel R Dumon; Kendra D Conzen; Trevor L Nydam
Journal:  J Gastrointest Surg       Date:  2019-05-01       Impact factor: 3.452

4.  Re-examining the BMI threshold for bariatric surgery in the USA.

Authors:  Rashikh A Choudhury; K M Murayama; C J Neylan; G Savulionyte; H A Glick; N N Williams; D T Dempsey; K R Dumon
Journal:  J Gastrointest Surg       Date:  2014-10-09       Impact factor: 3.452

5.  Safety analysis of primary bariatric surgery in patients on chronic dialysis.

Authors:  Amin Andalib; Ali Aminian; Zhamak Khorgami; Sankar D Navaneethan; Philip R Schauer; Stacy A Brethauer
Journal:  Surg Endosc       Date:  2015-09-28       Impact factor: 4.584

6.  Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.

Authors:  Rashikh Choudhury; Christopher D Barrett; Hunter B Moore; Ernest E Moore; Robert C McIntyre; Peter K Moore; Daniel S Talmor; Trevor L Nydam; Michael B Yaffe
Journal:  World J Emerg Surg       Date:  2020-04-20       Impact factor: 5.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.